$HCSG
HEALTHCARE SERVICES GROUP INC Stock $hcsg

$hcsg Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-Q Financial Statement

#000073101217000054 Filed on April 28, 2017

Income Statement

Concept	2017 Q1	2016 Q1
Revenue	$404.5M	$384.8M
YoY Change	5.12%	8.32%
Cost Of Revenue	$345.6M	$330.0M
YoY Change	4.7%	8.59%
Gross Profit	$58.92M	$54.76M
YoY Change	7.59%	6.73%
Gross Profit Margin	14.57%	14.23%
Selling, General & Admin	$28.21M	$25.35M
YoY Change	11.3%	-5.29%
% of Gross Profit	47.88%	46.28%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.886M	$1.965M
YoY Change	-4.02%	2.83%
% of Gross Profit	3.2%	3.59%
Operating Expenses	$28.21M	$25.35M
YoY Change	11.3%	-5.29%
Operating Profit	$30.71M	$29.42M
YoY Change	4.4%	19.84%
Interest Expense	$1.600M	$200.0K
YoY Change	700.0%	-60.0%
% of Operating Profit	5.21%	0.68%
Other Income/Expense, Net
YoY Change
Pretax Income	$32.28M	$29.60M
YoY Change	9.04%	18.16%
Income Tax	$10.26M	$10.98M
% Of Pretax Income	31.79%	37.08%
Net Earnings	$22.02M	$18.63M
YoY Change	18.21%	20.04%
Net Earnings / Revenue	5.44%	4.84%
Basic Earnings Per Share	$0.30	$0.26
Diluted Earnings Per Share	$0.30	$0.26
COMMON SHARES
Basic Shares Outstanding	73.07M shares	72.36M shares
Diluted Shares Outstanding	73.95M shares	73.01M shares

Balance Sheet

Concept	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$116.5M	$101.5M
YoY Change	14.78%	44.79%
Cash & Equivalents	$48.23M	$29.12M
Short-Term Investments	$68.30M	$72.40M
Other Short-Term Assets	$16.80M	$15.70M
YoY Change	7.01%	18.94%
Inventory	$37.30M	$37.90M
Prepaid Expenses	$16.82M	$14.77M
Receivables	$281.1M	$236.4M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$451.7M	$391.5M
YoY Change	15.38%	18.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.40M	$13.28M
YoY Change	0.92%	1.62%
Goodwill	$44.44M	$44.44M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$48.00K	$44.00K
YoY Change	9.09%	15.79%
Total Long-Term Assets	$113.4M	$111.6M
YoY Change	1.61%	-15.46%
TOTAL ASSETS
Total Short-Term Assets	$451.7M	$391.5M
Total Long-Term Assets	$113.4M	$111.6M
Total Assets	$565.1M	$503.1M
YoY Change	12.33%	8.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$47.95M	$39.77M
YoY Change	20.56%	-6.73%
Accrued Expenses	$61.30M	$62.80M
YoY Change	-2.39%	22.9%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$117.7M	$102.6M
YoY Change	14.69%	2.63%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$91.00M	$87.50M
YoY Change	4.0%	13.34%
Total Long-Term Liabilities	$91.00M	$87.50M
YoY Change	4.0%	13.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$117.7M	$102.6M
Total Long-Term Liabilities	$91.00M	$87.50M
Total Liabilities	$208.6M	$190.1M
YoY Change	9.73%	7.28%
SHAREHOLDERS EQUITY
Retained Earnings	$139.3M	$112.4M
YoY Change	24.01%	8.98%
Common Stock	$226.8M	$210.2M
YoY Change	7.91%	9.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$9.835M	$10.69M
YoY Change	-7.97%	-1.54%
Treasury Stock Shares	1.541M shares	1.699M shares
Shareholders Equity	$356.5M	$313.0M
YoY Change
Total Liabilities & Shareholders Equity	$565.1M	$503.1M
YoY Change	12.33%	8.84%

Cashflow Statement

Concept	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	$22.02M	$18.63M
YoY Change	18.21%	20.04%
Depreciation, Depletion And Amortization	$1.886M	$1.965M
YoY Change	-4.02%	2.83%
Cash From Operating Activities	$34.65M	$9.689M
YoY Change	257.58%	-256.17%
INVESTING ACTIVITIES
Capital Expenditures	$1.325M	$1.459M
YoY Change	-9.18%	1.6%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$2.200M
YoY Change	-100.0%	2100.0%
Cash From Investing Activities	-$1.356M	-$3.671M
YoY Change	-63.06%	138.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$24.00K	$28.00K
YoY Change	-14.29%	7.69%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$8.913M	-$10.09M
YoY Change	-11.64%	9.1%
NET CHANGE
Cash From Operating Activities	$34.65M	$9.689M
Cash From Investing Activities	-$1.356M	-$3.671M
Cash From Financing Activities	-$8.913M	-$10.09M
Net Change In Cash	$24.38M	-$4.069M
YoY Change	-699.09%	-76.05%
FREE CASH FLOW
Cash From Operating Activities	$34.65M	$9.689M
Capital Expenditures	$1.325M	$1.459M
Free Cash Flow	$33.32M	$8.230M
YoY Change	304.87%	-207.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000731012
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	72989000	shares
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	HEALTHCARE SERVICES GROUP INC
CY2016Q4	hcsg	Concentration Risk Numberof Financial Institutions Holding Cashand Cash Equivalentsand Marketable Securities ConcentrationRiskNumberofFinancialInstitutionsHoldingCashandCashEquivalentsandMarketableSecurities	1	financial_institution
CY2017Q1	hcsg	Concentration Risk Numberof Financial Institutions Holding Cashand Cash Equivalentsand Marketable Securities ConcentrationRiskNumberofFinancialInstitutionsHoldingCashandCashEquivalentsandMarketableSecurities	1	financial_institution
CY2016Q1	hcsg	Deferred Income Tax Expense Benefit Excluding Tax Benefit From Equity Compensation Plans DeferredIncomeTaxExpenseBenefitExcludingTaxBenefitFromEquityCompensationPlans	3395000	USD
CY2017Q1	hcsg	Deferred Income Tax Expense Benefit Excluding Tax Benefit From Equity Compensation Plans DeferredIncomeTaxExpenseBenefitExcludingTaxBenefitFromEquityCompensationPlans	0	USD
CY2016Q1	hcsg	Increase Decrease In Deferred Compensation Funding IncreaseDecreaseInDeferredCompensationFunding	268000	USD
CY2017Q1	hcsg	Increase Decrease In Deferred Compensation Funding IncreaseDecreaseInDeferredCompensationFunding	-246000	USD
CY2016Q1	hcsg	Increase Decrease In Notes Receivable Long Term IncreaseDecreaseInNotesReceivableLongTerm	0	USD
CY2017Q1	hcsg	Increase Decrease In Notes Receivable Long Term IncreaseDecreaseInNotesReceivableLongTerm	-475000	USD
CY2017Q1	hcsg	Line Of Credit Facility Number Of Financial Covenants LineOfCreditFacilityNumberOfFinancialCovenants	1	financial_covenant
CY2017Q1	hcsg	Lineof Credit Facility Increase Decrease Remaining Borrowing Capacity LineofCreditFacilityIncreaseDecreaseRemainingBorrowingCapacity	-67200000	USD
CY2017Q1	hcsg	Period Of Amortization Of Inventories And Supplies PeriodOfAmortizationOfInventoriesAndSupplies	P24M
CY2016Q1	hcsg	Related Party Transaction Fees Paid Related Party As Percentage Of Overall Related Party Revenues RelatedPartyTransactionFeesPaidRelatedPartyAsPercentageOfOverallRelatedPartyRevenues	0.05
CY2017Q1	hcsg	Related Party Transaction Fees Paid Related Party As Percentage Of Overall Related Party Revenues RelatedPartyTransactionFeesPaidRelatedPartyAsPercentageOfOverallRelatedPartyRevenues	0.05
CY2017Q1	hcsg	Service Agreements Duration Of Service ServiceAgreementsDurationOfService	P1Y
CY2017Q1	hcsg	Share Based Compensation Arrangement By Share Based Payment Award Maximum Term Of Grants ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumTermOfGrants	P10Y
CY2016Q1	hcsg	Share Based Compensation Shares Authorized Under Stock Option Plan Exercise Price Range Exercisable Options Weighted Average Exercise Price ShareBasedCompensationSharesAuthorizedUnderStockOptionPlanExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice	32.45
CY2017Q1	hcsg	Share Based Compensation Shares Authorized Under Stock Option Plan Exercise Price Range Exercisable Options Weighted Average Exercise Price ShareBasedCompensationSharesAuthorizedUnderStockOptionPlanExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice	39.38
CY2016Q1	hcsg	Unrealized Gain Loss On Securities Related To Deferred Compensation Fund UnrealizedGainLossOnSecuritiesRelatedToDeferredCompensationFund	-278000	USD
CY2017Q1	hcsg	Unrealized Gain Loss On Securities Related To Deferred Compensation Fund UnrealizedGainLossOnSecuritiesRelatedToDeferredCompensationFund	1209000	USD
CY2016Q4	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	271276000	USD
CY2017Q1	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	281113000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	42912000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	47952000	USD
CY2016Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	7686000	USD
CY2017Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	8403000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20564000	USD
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	21144000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-319000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	160000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	217664000	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	226075000	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1459000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1118000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1580000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6911000	USD
CY2017Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	7698000	USD
CY2016Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	800000	USD
CY2017Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1000000	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	500000	shares
CY2016Q4	us-gaap	Assets Assets	528446000	USD
CY2017Q1	us-gaap	Assets Assets	565108000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	414624000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	451721000	USD
CY2016Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	178000	USD
CY2017Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	477000	USD
CY2016Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	668000	USD
CY2017Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	230000	USD
CY2016Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	68220000	USD
CY2017Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	68013000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	21651000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	24076000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	28671000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	18021000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	16435000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	25379000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	973000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	784000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	67730000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	68260000	USD
CY2016Q1	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	62000	USD
CY2017Q1	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	-48000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33189000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29120000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23853000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48230000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4069000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	24377000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3700000	shares
CY2017Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.18625
CY2016Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.18250
CY2017Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.18750
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74204000	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74423000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72601000	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72882000	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	742000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	744000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	19181000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	22496000	USD
CY2016Q1	us-gaap	Cost Of Services CostOfServices	330044000	USD
CY2017Q1	us-gaap	Cost Of Services CostOfServices	345570000	USD
CY2016Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	24653000	USD
CY2017Q1	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	26386000	USD
CY2016Q4	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	24119000	USD
CY2017Q1	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	25082000	USD
CY2016Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	9822000	USD
CY2017Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	9564000	USD
CY2016Q1	us-gaap	Depreciation Depreciation	1200000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	1300000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1965000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1886000	USD
CY2017Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	13624000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.26
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.30
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.26
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.30
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22303000	USD
CY2017Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	34334000	USD
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	15200000	USD
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y6M
CY2016Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	509000	USD
CY2017Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	0	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14672000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	15279000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1134000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2328000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1820000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2130000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2130000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2130000	USD
CY2016Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	11201000	USD
CY2017Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	9544000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	22899000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2130000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	29081000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	29081000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14409000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	13802000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	44438000	USD
CY2017Q1	us-gaap	Goodwill Goodwill	44438000	USD
CY2016	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2017Q1	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	29604000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	32279000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10978000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10262000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	10887000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-3618000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	1852000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	100000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	1059000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1619000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-506000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-4100000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	3639000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	18070000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	15299000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3277000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2859000	USD
CY2016Q1	us-gaap	Increase Decrease In Workers Compensation Liabilities IncreaseDecreaseInWorkersCompensationLiabilities	1009000	USD
CY2017Q1	us-gaap	Increase Decrease In Workers Compensation Liabilities IncreaseDecreaseInWorkersCompensationLiabilities	784000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	155000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	204000	USD
CY2016Q1	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	318000	USD
CY2017Q1	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	343000	USD
CY2016Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	187000	USD
CY2017Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1569000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	528446000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	565108000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	100871000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	117664000	USD
CY2017Q1	us-gaap	Line Of Credit LineOfCredit	0	USD
CY2017Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	200000000	USD
CY2017Q1	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	132800000	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3118000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	48000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	48000	USD
CY2016Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	67730000	USD
CY2017Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	68260000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-10087000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-8913000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3671000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1356000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	9689000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	34646000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	18626000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	22017000	USD
CY2016Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	7531000	USD
CY2017Q1	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	7056000	USD
CY2017Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2016Q1	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	594000	USD
CY2017Q1	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	446000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4397000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	300000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	300000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	555000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	479000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	555000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	479000	USD
CY2016Q4	us-gaap	Other Inventory OtherInventory	37800000	USD
CY2017Q1	us-gaap	Other Inventory OtherInventory	37294000	USD
CY2016Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	13158000	USD
CY2017Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	13600000	USD
CY2017Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	13624000	USD
CY2016Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	4966000	USD
CY2017Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	7858000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1459000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1325000	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	13965000	USD
CY2017Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	16824000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	24000	USD
CY2016Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2640000	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	7723000	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	2000000	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	7500000	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	114000	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	104000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4687000	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2534000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.251
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.020
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	34019000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	34541000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13455000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13397000	USD
CY2016Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1100000	USD
CY2017Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1050000	USD
CY2016Q1	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	39000	USD
CY2017Q1	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-33000	USD
CY2016Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	120000	USD
CY2017Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	120000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	130940000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	139333000	USD
CY2016Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	384807000	USD
CY2017Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	404490000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25346000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	28210000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	609000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	445000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P5Y
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.020
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.019
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.260
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.020
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	700000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1437000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	20.50
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1700000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3500000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	39000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	33.82
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	544000	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.46
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.52
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	46007000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2615000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2919000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	24.61
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	27.33
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	23.31
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	39.38
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	32464000	USD
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y9M
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73946000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72364000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73074000	shares
CY2016Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	23573000	USD
CY2017Q1	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	23857000	USD
CY2016Q4	us-gaap	Workers Compensation Liability Noncurrent WorkersCompensationLiabilityNoncurrent	64080000	USD
CY2017Q1	us-gaap	Workers Compensation Liability Noncurrent WorkersCompensationLiabilityNoncurrent	64581000	USD
CY2017Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2016Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	650000	shares
CY2017Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	872000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73014000	shares
CY2017Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y8M
CY2017Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	201000	shares
CY2017Q1	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	24000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	502000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2091000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4687000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	338842000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	356477000	USD
CY2016Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1603000	shares
CY2017Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	1541000	shares
CY2016Q4	us-gaap	Treasury Stock Value TreasuryStockValue	10185000	USD
CY2017Q1	us-gaap	Treasury Stock Value TreasuryStockValue	9835000	USD
CY2017Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments that are subject to concentrations of credit risk are cash and cash equivalents, marketable securities, deferred compensation funding and accounts and notes receivable. We define our marketable securities as fixed income investments which are highly liquid and can be readily purchased or sold through established markets. At </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, substantially all of our cash and cash equivalents and marketable securities were held in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> large financial institution located in the United States.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our clients are concentrated in the health care industry and are primarily providers of long-term care. Many of our clients’ revenues are highly reliant on Medicare, Medicaid and third party payors’ reimbursement funding rates. New legislation or changes in existing regulations could be made which could directly impact the governmental reimbursement programs in which our clients participate. As a result, we may not know the full effects of such programs until these laws are fully implemented and governmental agencies issue applicable regulations or guidance. </font></div></div>
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In preparing financial statements in conformity with U.S. GAAP, we make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities, and the reported amounts of revenues and expenses. Actual results could differ from those estimates. Significant estimates are used in determining, but are not limited to, our allowance for doubtful accounts, accrued insurance claims, asset valuations, deferred taxes and reviews for potential impairment. The estimates are based upon various factors including current and historical trends, as well as other pertinent industry and regulatory authority information. We regularly evaluate this information to determine if it is necessary to update the basis for our estimates and to adjust for known changes.</font></div></div>

Files In Submission

Name	View Source	Status
0000731012-17-000054-index-headers.html	Edgar Link	pending
0000731012-17-000054-index.html	Edgar Link	pending
0000731012-17-000054.txt	Edgar Link	pending
0000731012-17-000054-xbrl.zip	Edgar Link	pending
ceosection302certification.htm	Edgar Link	pending
cfosection302certification.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hcsg-20170331.xml	Edgar Link	completed
hcsg-20170331.xsd	Edgar Link	pending
hcsg-20170331_cal.xml	Edgar Link	unprocessable
hcsg-20170331_def.xml	Edgar Link	unprocessable
hcsg-20170331_lab.xml	Edgar Link	unprocessable
hcsg-20170331_pre.xml	Edgar Link	unprocessable
hcsg10qq12017.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
section906certificationq12.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HCSG
HEALTHCARE SERVICES GROUP INC Stock $hcsg

2017 Q1 Form 10-Q Financial Statement

#000073101217000054 Filed on April 28, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCSG HEALTHCARE SERVICES GROUP INC Stock $hcsg

2017 Q1 Form 10-Q Financial Statement

#000073101217000054 Filed on April 28, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCSG
HEALTHCARE SERVICES GROUP INC Stock $hcsg